MGRXNasdaqServices-Misc Health & Allied Services, NECFiscal year ends December 31
MANGOCEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.28−0.01 (-3.38%)
Close on Oct 19, 2026
- Market cap
- $4.80M
- P/E (TTM)
- –
- Dividend yield
- –
Mangoceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Services-Misc Health & Allied Services, NEC companies for comparison
Valuation
| Measure | Mangoceuticals | Industry median |
|---|---|---|
| Market Cap | $6.04M | $1.11B |
| Enterprise Value | $5.81M | $1.41B |
| PS Ratio | 19.16 | 1.60 |
| PB Ratio | 0.48 | 3.03 |
Enterprise value
| Measure | Mangoceuticals | Industry median |
|---|---|---|
| EV / Sales | 18.43 | 1.69 |
Income (trailing twelve months)
| Measure | Mangoceuticals | Industry median |
|---|---|---|
| Revenue | $315.23K | $561.90M |
| Gross Profit | $171.59K | $173.32M |
| Operating Income | -$12.07M | -$1.81M |
| Pretax Income | -$15.10M | -$572.42K |
| Net Income | -$15.10M | -$1.16M |
| EBITDA | -$12.07M | -$20.72K |
| EPS (Diluted) | -$1.22 | -$0.02 |
Margins
| Measure | Mangoceuticals | Industry median |
|---|---|---|
| Gross Margin | 54.4% | 33.1% |
| Operating Margin | -3829.0% | -4.45% |
| Pretax Margin | -4791.5% | 1.54% |
| Profit Margin | -4791.3% | -2.91% |
| EBITDA Margin | -3829.0% | 2.41% |
Returns
| Measure | Mangoceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | -95.1% | 1.84% |
| Return on Assets (ROA) | -86.3% | -3.06% |
| Return on Invested Capital (ROIC) | -60.7% | 2.11% |
| Return on Capital Employed (ROCE) | -94.5% | -0.57% |
Growth
| Measure | Mangoceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -38.9% | 6.92% |
| Revenue Growth (3Y CAGR) | 270.9% | 10.9% |
Balance sheet
| Measure | Mangoceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $228.69K | $48.71M |
| Net Cash (Debt) | $228.69K | $205.49K |
| Net Cash Per Share | $0.01 | $0.01 |
| Equity (Book Value) | $12.53M | $235.16M |
| Book Value Per Share | $0.58 | $3.48 |
| Tangible Book Value | -$1.12M | $703.69K |
| Working Capital | -$1.15M | $30.48M |
Financial position
| Measure | Mangoceuticals | Industry median |
|---|---|---|
| Current Ratio | 0.18 | 1.40 |
| Quick Ratio | 0.16 | 1.02 |
Cash flow (trailing twelve months)
| Measure | Mangoceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$3.89M | $3.10M |
Efficiency
| Measure | Mangoceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.02 | 0.87 |
Dividends and yields
| Measure | Mangoceuticals | Industry median |
|---|---|---|
| Earnings Yield | -250.0% | -0.59% |
Shares
| Measure | Mangoceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 21,567,400 | 58,282,400 |
| Shares Change (YoY) | 208.8% | 2.68% |
| Shares Change (QoQ) | 6.19% | 0.32% |
| Float | 12,095,800 | 33,780,100 |
| Shares Held by Insiders | 43.9% | 16.4% |
| Shares Held by Institutions | 5.57% | 85.9% |
Scores
| Measure | Mangoceuticals | Industry median |
|---|---|---|
| Altman Z-Score | -5.17 | 2.05 |
| Piotroski F-Score | 3 | 5 |
Calculated by StockData from Mangoceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.